Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.50 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945800 | 0.88 | TLR7 (0.60) | TLR7TLR8NSD2NSD3PNP | |
| SCHEMBL19945683 | 0.88 | TLR7 (0.55) | TLR7TLR8NSD2NSD3TRAP1 | |
| SCHEMBL29488793 | 0.80 | TLR7 (0.67) | TLR7TLR8TRAP1HSP90B1NUDT1 | |
| SCHEMBL18207673 | 0.80 | TLR7 (0.67) | TLR7TLR8TRAP1HSP90B1NUDT1 | |
| SCHEMBL7681629 | 0.77 | PNP (0.80) | TLR7TLR8BRD4BRD2BRD3 | |
| SCHEMBL18207308 | 0.76 | TLR7 (0.65) | TLR7TLR8NUDT1 | |
| SCHEMBL21287888 | 0.75 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL7682667 | 0.75 | PNP (0.60) | TLR7TLR8TRAP1BRD4BRD2 | |
| SCHEMBL18207528 | 0.74 | TLR7 (0.63) | TLR7TLR8NUDT1 | |
| SCHEMBL18207518 | 0.74 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970750-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| WO-2018050571-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |